anti-SARS-CoV-2 human convalescent plasma

BIOLOGICAL2 trials

Sponsors

Johns Hopkins University, University of California, Los Angeles

Conditions

Corona Virus InfectionSARS-CoV-2 Infection

Phase 1

Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)

CompletedNCT04377672

Johns Hopkins UniversitySARS-CoV-2 Infection

Start: 2020-05-28End: 2021-12-13Updated: 2024-03-27

Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions

University of California, Los AngelesCorona Virus Infection

Start: 2020-08-31End: 2024-12-31Target: 30Updated: 2020-07-08

Related Papers

Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children

JCI Insight2021-12-0224 citations